The need for a subsequent transvenous system in patients implanted with subcutaneous implantable cardioverter defibrillator.

[1]  OUP accepted manuscript , 2022, European Heart Journal.

[2]  P. Lambiase,et al.  Efficacy and Safety of Appropriate Shocks and Antitachycardia Pacing in Transvenous and Subcutaneous Implantable Defibrillators: Analysis of All Appropriate Therapy in the PRAETORIAN Trial , 2021, Circulation.

[3]  M. Glikson,et al.  The '10 commandments' for the 2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy. , 2021, European heart journal.

[4]  A. Natale,et al.  Intraprocedural PRAETORIAN score for early assessment of S‐ICD implantation: A proof‐of‐concept study , 2021, Journal of cardiovascular electrophysiology.

[5]  A. Curnis,et al.  Long term complications in patients implanted with subcutaneous implantable defibrillators Real-world data from the Extended ELISIR experience. , 2021, Heart rhythm.

[6]  L. Di Biase,et al.  Subcutaneous implantable cardioverter defibrillator and defibrillation testing: a propensity-matched pilot study. , 2021, Heart rhythm.

[7]  P. Lambiase,et al.  Device-related Infection in De Novo Transvenous Implantable Cardioverter-Defibrillator Medicare Patients. , 2021, Heart rhythm.

[8]  M. Biffi,et al.  Clinical impact of defibrillation testing in a real‐world S‐ICD population: Data from the ELISIR registry , 2020, Journal of cardiovascular electrophysiology.

[9]  M. Casula,et al.  Subcutaneous versus Transvenous Implantable Defibrillator: an updated Meta-analysis. , 2020, Heart rhythm.

[10]  A. Curnis,et al.  Neglected lead tip erosion: An unusual case of S‐ICD inappropriate shock , 2020, Journal of cardiovascular electrophysiology.

[11]  P. Lambiase,et al.  Subcutaneous or Transvenous Defibrillator Therapy , 2020, New England Journal of Medicine.

[12]  George A. Johnson,et al.  Long-Term Outcomes of Implantable Cardioverter-Defibrillator Therapy in the SCD-HeFT. , 2020, Journal of the American College of Cardiology.

[13]  R. Khouzam,et al.  Implantable Cardioverter Defibrillators and Chronic Kidney Disease. , 2020, Current problems in cardiology.

[14]  W. Zareba,et al.  Need for pacing in patients who qualify for an implantable cardioverter‐defibrillator: Clinical implications for the subcutaneous ICD , 2020, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

[15]  M. Biffi,et al.  Successful defibrillation verification in subcutaneous implantable cardioverter‐defibrillator recipients by low‐energy shocks , 2019, Clinical cardiology.

[16]  A. Wilde,et al.  A novel tool to evaluate the implant position and predict defibrillation success of the subcutaneous implantable cardioverter-defibrillator: The PRAETORIAN score. , 2019, Heart rhythm.

[17]  F. Prinzen,et al.  Atrioventricular dromotropathy: evidence for a distinctive entity in heart failure with prolonged PR interval? , 2018, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[18]  J. DiNicolantonio,et al.  Subcutaneous Versus Transvenous Implantable Defibrillator Therapy: A Meta-Analysis of Case-Control Studies. , 2017, JACC. Clinical electrophysiology.

[19]  A. Wilde,et al.  Long-Term Clinical Outcomes of Subcutaneous Versus Transvenous Implantable Defibrillator Therapy. , 2016, Journal of the American College of Cardiology.

[20]  M. Falagas,et al.  Risk factors for cardiac implantable electronic device infection: a systematic review and meta-analysis. , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[21]  A. Auricchio,et al.  Low inappropriate shock rates in patients with single- and dual/triple-chamber implantable cardioverter-defibrillators using a novel suite of detection algorithms: PainFree SST trial primary results. , 2015, Heart rhythm.

[22]  Pier D. Lambiase,et al.  Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-Year Results From a Pooled Analysis of the IDE Study and EFFORTLESS Registry. , 2015, Journal of the American College of Cardiology.

[23]  D. Babuty,et al.  Reduced risk for inappropriate implantable cardioverter-defibrillator shocks with dual-chamber therapy compared with single-chamber therapy: results of the randomized OPTION study. , 2014, JACC. Heart failure.

[24]  P. Lambiase,et al.  Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry , 2014, European heart journal.

[25]  C. Swerdlow,et al.  Antitachycardia Pacing in Primary‐Prevention ICDs , 2010, Journal of cardiovascular electrophysiology.

[26]  J. Jiménez-Candil,et al.  Influence of beta-blocker therapy on antitachycardia pacing effectiveness for monomorphic ventricular tachycardias occurring in implantable cardioverter-defibrillator patients: a dose-dependent effect. , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[27]  Alexander H Maass,et al.  An entirely subcutaneous implantable cardioverter-defibrillator. , 2010, The New England journal of medicine.

[28]  A. Camm,et al.  Single-chamber versus dual-chamber pacing for high-grade atrioventricular block. , 2005, The New England journal of medicine.